



I, Karen Lee, hereby certify that I am competent to translate from Chinese to English and that the attached translation is, to the best of my knowledge and belief, a true and accurate translation of the following document from Chinese to English.

Excerpt from Ex. 2015 - Bio-Thera Solutions, Ltd. 2019 Annual Report (Chinese)

A handwritten signature in black ink, appearing to read 'K Lee', written over a horizontal line.

Karen Lee

Sworn to before me this
June 15, 2026

A handwritten signature in black ink, appearing to read 'M Lezhnev', written over a horizontal line.

Signature, Notary Public

Mikhail E. Lezhnev
Notary Public ID No. 02LE0003393
State of New York Qualified in Kings County
Commission Expires on March 22, 2027

Stamp, Notary Public

LANGUAGE AND TECHNOLOGY SOLUTIONS FOR GLOBAL BUSINESS

1250 BROADWAY, 7TH FLOOR, NEW YORK, NY 10001 | T 212.689.5555 | F 212.689.1059 |

WWW.TRANSPERFECT.COM OFFICES IN 92 CITIES WORLDWIDE

Accord BioPharma, Inc.
Exhibit 1093

Accord v. Janssen
IPR2026-00256, -00257, -00258, -00259
Ex. 1093-001

Stock code: 688177

Stock abbreviation: Bio-Thera

Bio-Thera Solutions, Ltd. 2019 Annual Report



Contents

Section I	Definitions	6
Section II	Company Profile and Key Financial Indicators.....	10
Section III	Summary of Company Business.....	15
Section IV	Discussion and Analysis of Operations	34
Section V	Significant Events	62
Section VI	Changes in Shares and Shareholder Information	95
Section VII	Information Relating to Preferred Shares.....	106
Section VIII	Directors, Supervisors, Senior Management, and Employees.....	107
Section IX	Corporate Governance.....	118
Section X	Information Relating to Corporate Bonds.....	121
Section XI	Financial Report	122
Section XII	Documents Available for Inspection	236

☐ Applicable ☒ Not Applicable

(II) Changes in the total number of ordinary shares and shareholder structure of the Company, and changes in the Company's asset and liability structure

☐ Applicable ☒ Not Applicable

III. Shareholders and actual controllers

(I) Total number of shareholders

Total number of ordinary shareholder accounts as of the end of the reporting period	15
Total number of ordinary shareholder accounts as of the end of the month preceding the disclosure date of the annual report	18,254
Total number of preferred shareholder accounts with restored voting rights as of the end of the reporting period	0
Total number of preferred shareholder accounts with restored voting rights as of the end of the month preceding the disclosure date of the annual report	0

Number of depositary receipt holders

☐ Applicable ☒ Not Applicable

(II) Shareholdings of the top ten shareholders and top ten circulating shareholders (or shareholders without selling restrictions) as of the end of the reporting period

Unit: Shares

Unit: Shares

Shareholdings of the top ten shareholders								
Name of shareholder (Full name)	Increase/decrease during the reporting period	Number of shares held at the end of the period	Percentage (%)	Number of shares subject to selling restrictions held	Number of restricted shares including shares lent through securities lending and refinancing	Pledged or frozen shares		Nature of shareholder
						Share status	Quantity	
Guangzhou Qixi Group Co., Ltd.	0	159,990,270	45.18	159,990,270	0	None	0	Domestic non-state-owned legal person
Therabio International Limited	0	47,177,729	13.32	47,177,729	0	None	0	Foreign legal person
Guangzhou Qiao Xing Investment Partnership	0	23,173,326	6.54	23,173,326	0	None	0	Domestic non-state-owned legal person
Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership	2,400,000	21,559,471	6.09	21,559,471	0	None	0	Domestic non-state-owned legal person
Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership	0	21,333,332	6.03	21,333,332	0	None	0	Domestic non-state-owned legal person

Guangzhou Xingyu Investment Partnership	4,680,000	21,320,002	6.02	21,320,002	0	None	0	Domestic non-state-owned legal person
Guangzhou Shengyu Investment Partnership	16,000,000	16,000,000	4.52	16,000,000	0	None	0	Domestic non-state-owned legal person
Guangzhou Yichen Investment Enterprise	1,000,000	10,744,802	3.03	10,744,802	0	None	0	Domestic non-state-owned legal person
Guangzhou Fanwanhu Investment Partnership	0	7,424,586	2.10	7,424,586	0	None	0	Domestic non-state-owned legal person
LI SHENGFENG	0	6,517,332	1.84	6,517,332	0	None	0	Foreign natural person

Explanation of related-party relationships or persons acting in concert among the above shareholders	1. Related-party relationships: (1) Qixi Group is ultimately controlled by the actual controllers Yi Xianzhong, Guan Yuchan, and Yi Liangyu; (2) The general partner and executive partner of Xingyu Investment is Yi Liangyu and is ultimately controlled by Yi Liangyu; (3) The general partner and executive partner of Qiao Xing is Guan Yuchan and is ultimately controlled by Guan Yuchan; (4) Qixi Group holds a 74% limited partnership interest in Yuechuang No. 3, and Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, serves as the general partner of Yuechuang No. 3; (5) The general partner and executive partner of Shengyu Investment is Yi Xianzhong and is ultimately controlled by Yi Xianzhong; (6) The general partner and executive partner of CAS Zhuochuang is Yuechuang Incubator, in which Guan Yuchan holds a 55% interest, and is ultimately controlled by Guan Yuchan. (7) Therabio International is a company 100% owned by LI SHENGFENG; (8) Fanwanhu is a limited partnership in which LI SHENGFENG and his children contribute 100% of the capital, and LI SHENGFENG serves as the general partner and executive partner. (9) The general partner and executive partner of Jifu Qiheng, Jifu Venture Capital Co., Ltd., directly and indirectly holds an aggregate 100% equity interest in Hefei Jiqiang Equity Investment Management Partnership (Limited Partnership), the general partner and executive partner of Hefei Qixing; (10) Dong Zhengqing, the controlling shareholder of Huitianze (holding 98.8% of Huitianze's equity), is also the largest shareholder of Jifu Venture Capital Co., Ltd. (holding 28.3195% of its shares); (11) Huitianze is also the largest shareholder of Huizhifu (holding 38.92% of its equity). 2. Persons acting in concert (1) Controlling shareholder Qixi Group and its persons acting in concert: Guangzhou Qiao Xing Investment Partnership (Limited Partnership), Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership (Limited Partnership), Guangzhou Xingyu Investment Partnership (Limited Partnership), Guangzhou Shengyu Investment Partnership (Limited Partnership), and Hengqin CAS Zhuochuang Equity Investment Fund Partnership (Limited Partnership); (2) Therabio International Limited and its person acting in concert, Guangzhou Fanwanhu Investment Partnership (Limited Partnership); (3) Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership (Limited Partnership) and its persons acting in concert: Hefei Qixing Equity Investment Partnership (Limited Partnership), Huitianze Investment Co., Ltd., and Anhui Huizhifu Venture Capital Co., Ltd.
Explanation of preferred shareholders with restored voting rights and the number of shares held	Not applicable

Number of shares held by the top ten shareholders subject to selling restrictions and the selling restrictions

√ Applicable □ Not applicable

Unit: shares

No.	Name of shareholder subject to selling restrictions	Number of shares subject to selling restrictions held	Listing and trading status of shares subject to selling restrictions		Selling restrictions
			Date tradable on the market	Number of newly tradable shares	
1	Guangzhou Qixi Group Co., Ltd.	159,990,270	2023-2-21	0	36 months
2	Therabio International Limited	47,177,729	2021-2-21	0	12 months

3	Guangzhou Qiao Xing Investment Partnership	23,173,326	2023-2-21	0	36 months
4	Zhuhai Jifu Qiheng Pharmaceutical Investment Partnership	21,559,471	2021-2-21	0	12 months, 36 months (2.4 million shares acquired through a capital increase within six months prior to the Company's filing for issuance and listing shall not be transferred within 36 months from March 26, 2019; the remaining shares are subject to a 12-month lock-up period)
5	Guangzhou CAS Yuechuang No. 3 Venture Capital Partnership	21,333,332	2023-2-21	0	36 months
6	Guangzhou Xingyu Investment Partnership	21,320,002	2023-2-21	0	36 months
7	Guangzhou Shengyu Investment Partnership	16,000,000	2023-2-21	0	36 months
8	Guangzhou Yichen Investment Enterprise	10,744,802	2021-2-21	0	12 months, 36 months (1 million shares acquired through a capital increase within six months prior to the Company's filing for issuance and listing shall not be transferred within 36 months from March 26, 2019; the remaining shares are subject to a 12-month lock-up period)
9	Guangzhou Fanwanhu Investment Partnership	7,424,586	2021-2-21	0	12 months
10	LI SHENGFENG	6,517,332	2021-2-21	0	12 months (prior to the Company achieving profitability, no reduction of pre-IPO shares shall be made during the first three complete fiscal years from the date of the Company's stock listing)
Explanation of related-party relationships or persons acting in concert among the above shareholders		See "Section VI. Changes in Shares and Shareholder Information" – "III. Shareholders and Actual Controllers" above.			

Note: For the selling restrictions applicable to the top ten shareholders subject to selling restrictions, see "Section V. Significant Events" – "II. Performance of Commitments" of this report.

Table of the top 10 domestic depositary receipt holders as of the end of the reporting period

☐ Applicable ☒ Not Applicable

Number of depositary receipts held by the top ten holders of depositary receipts subject to selling restrictions and the selling restrictions

☐ Applicable ☒ Not Applicable

(III) Table of the top ten shareholders by voting rights as of the end of the reporting period

☐ Applicable ☒ Not Applicable

(IV) Strategic investors or general legal persons becoming top 10 shareholders through placement of new shares/depositary receipts

☐ Applicable ☒ Not Applicable

(V) Strategic placement in the initial public offering**1. Holdings under special asset management plans established by senior management and core employees participating in the strategic placement of the initial public offering**

☐ Applicable ☒ Not Applicable

2. Shareholding by relevant subsidiaries of the sponsor institution participating in the strategic placement of the initial public offering

☐ Applicable ☒ Not Applicable

IV. Controlling shareholder and actual controllers**(I) Information on the controlling shareholder****1 Legal person**

☒ Applicable ☐ Not Applicable

Name	Guangzhou Qixi Group Co., Ltd.
Principal person in charge or legal representative	Yi Xianzhong
Date of establishment	April 6, 2000
Principal business activities	"Investment with proprietary corporate funds; asset management (excluding projects requiring licensing and approval); property management; logistics support services for organizations (excluding projects requiring licensing); retail trade of commodities (excluding commodities requiring licensing and approval); office equipment leasing services; property leasing; wholesale trade of commodities (excluding commodities requiring licensing and approval); investment management services; investment consulting services; market research services; software development; information technology consulting services; digital animation production." Its principal business is investment management.
Equity interests in other domestic and overseas listed companies controlled or participated in during the reporting period	None
Other information	None

2 Natural person

☐ Applicable ☒ Not Applicable

3 Special explanation where the Company has no controlling shareholder


☐ Applicable ☒ Not Applicable

4 Reference and date of changes in the controlling shareholder during the reporting period

☐ Applicable ☒ Not Applicable

5 Diagram of the property rights and control relationship between the Company and its controlling shareholder

√ Applicable □ Not Applicable



(Note: GP means General Partner)